Chiron deal

Quarterly product sales grew to $50.1 million from $28.6 million, due to increased product sales from the Chiron Vision ophthalmic business, and $10.5 million in initial shipments of Betaseron (Interferon beta-1b) to Berlex Laboratories.

R&D expenses dropped to $38.5 million from $51.1 million in the 1992 quarter. The 1992 quarter included a $4 million charge for the early retirement of debt. ...